Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: contrarian who wrote (1483)	2/12/1998 7:15:00 PM
From: Roudy	Respond to of 1762

Hi Contrarian, I can give you a view on the P&F chart analysis. The chart is still bullish and a price move to 45 would indicate another breakout and triple top buy signal. The P&F chart is very bullish on IDPH currently. Don

To: contrarian who wrote (1483)	2/12/1998 10:25:00 PM
From: Roger Cranwill	Read Replies (1) \| Respond to of 1762

The California state social services program (welfare program) is called Medi-Cal. The Medi-Cal bureaucracy furnishes each "health provider" with a compendium of drugs they'll pay for-most drugs are stipulated as to the exact strength, duration of action (they normally don't cover longer acting forms), and on certain drugs, specific diagnosis. What's interesting in Rituximab's case (they list all drugs by generic name only) is that no stipulation of diagnosis is listed....very interesting. Roger